IDEAYA Biosciences (IDYA)
(Delayed Data from NSDQ)
$42.25 USD
-0.14 (-0.33%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $42.23 -0.02 (-0.05%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
IDEAYA Biosciences, Inc. [IDYA]
Reports for Purchase
Showing records 41 - 60 ( 172 total )
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
mUM Update Supports 1L Path; Q1:23 Registration Study Initiation
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Reports of the Death of Synthetic Lethality are Grossly Exaggerated
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
IDE397 GSK Option Package Delivered; Collaboration with Amgen?s PRMT5i
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare Coverage Update - Dropping Coverage
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
1Q2022 - Cash Balance and Upcoming Catalysts For Our Biotech Coverage Universe
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
1Q22 Update - Pipeline Progress & Model Update Supports Upping PT to $46
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials; IDE397 Continues to Progress; Darovasertib Updates Ahead
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Key Takeaways from Panels & Fireside Chats at Our 34th Annual ROTH Conference
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
IDE397 Synthetic Lethality Program Update - Incrementally Positive
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Daro + Crizotinib Data in MUM Exceeds Expectations - Raising PT to $42
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z